DK2252581T3 - Kappa-selektiv opioidreceptorantagonist - Google Patents

Kappa-selektiv opioidreceptorantagonist

Info

Publication number: DK2252581T3
Authority: DK; Denmark
Prior art keywords: cape; receptor antagonist; opioid receptor; selective opioid; selective
Prior art date: 2008-01-22

Application number

DK09703808.7T

Other languages

English (en)

Inventor

Buezo Nuria Diaz

David Lee Mckinzie

Charles Howard Mitch

Concepcion Pedregal-Tercero

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-22

Filing date

2009-01-13

Publication date

2012-07-16

2009-01-13 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2012-07-16 Application granted granted Critical

2012-07-16 Publication of DK2252581T3 publication Critical patent/DK2252581T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK09703808.7T 2008-01-22 2009-01-13 Kappa-selektiv opioidreceptorantagonist DK2252581T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08380012		2008-01-22
US3912108P	2008-03-25	2008-03-25
PCT/US2009/030811 WO2009094260A1 (en)	2008-01-22	2009-01-13	Kappa selective opioid receptor antagonist

Publications (1)

Publication Number	Publication Date
DK2252581T3 true DK2252581T3 (da)	2012-07-16

Family

ID=40876972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09703808.7T DK2252581T3 (da)	2008-01-22	2009-01-13	Kappa-selektiv opioidreceptorantagonist

Country Status (32)

Country	Link
US (2)	US7709522B2 (da)
EP (1)	EP2252581B1 (da)
JP (1)	JP5345637B2 (da)
KR (1)	KR101172170B1 (da)
CN (1)	CN101925576B (da)
AR (1)	AR070158A1 (da)
AU (1)	AU2009206653B2 (da)
BR (1)	BRPI0907382B8 (da)
CA (1)	CA2713025C (da)
CO (1)	CO6290644A2 (da)
CY (1)	CY1113071T1 (da)
DK (1)	DK2252581T3 (da)
DO (1)	DOP2010000222A (da)
EA (1)	EA017484B1 (da)
EC (1)	ECSP10010365A (da)
ES (1)	ES2388708T3 (da)
HR (1)	HRP20120558T1 (da)
IL (1)	IL206038A (da)
JO (1)	JO2797B1 (da)
MA (1)	MA32751B1 (da)
MX (1)	MX2010007849A (da)
MY (1)	MY163014A (da)
NZ (1)	NZ586225A (da)
PE (1)	PE20091317A1 (da)
PL (1)	PL2252581T3 (da)
PT (1)	PT2252581E (da)
SI (1)	SI2252581T1 (da)
TN (1)	TN2010000306A1 (da)
TW (1)	TWI422369B (da)
UA (1)	UA100715C2 (da)
WO (1)	WO2009094260A1 (da)
ZA (1)	ZA201003908B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ586225A (en) *	2008-01-22	2012-05-25	Lilly Co Eli	Kappa selective opioid receptor antagonist
UY31604A1 (es) *	2008-01-22	2009-08-31		Compuestos tricíclicos y uso de los mismos
EP2757881A4 (en)	2011-09-15	2014-11-12	Univ Kansas	KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
EP2758134B1 (en)	2011-09-19	2019-05-29	Carmel - Haifa University Economic Corporation Ltd.	Buprenorphine for the treatment of acute suicidality
US9512105B2 (en)	2011-12-09	2016-12-06	Research Triangle Institute	1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
EP2919788A4 (en)	2012-11-14	2016-05-25	Univ Johns Hopkins	METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
US9283196B1 (en)	2013-01-30	2016-03-15	MediSynergics, LLC	Cycloalkyl-diamines for CNS disorders
CA2911231C (en) *	2013-05-24	2021-12-07	Alkermes Pharma Ireland Limited	Morphan and morphinan analogues, and methods of use
US10316021B2 (en) *	2016-11-28	2019-06-11	Pfizer Inc.	Heteroarylphenoxy benzamide kappa opioid ligands
KR102656163B1 (ko)	2017-03-17	2024-04-08	더 스크립스 리서치 인스티튜트	카파 오피오이드 수용체 길항제 및 그와 관련된 제품 및 방법
JP6480616B1 (ja)	2018-02-08	2019-03-13	有限会社ディオン光学技研	照準スコープ
US11266627B1 (en)	2021-05-04	2022-03-08	Janssen Pharmaceuticals, Inc.	Compositions and methods for the treatment of depression
CN114195693A (zh) *	2020-09-17	2022-03-18	广东东阳光药业有限公司	一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) *	2020-12-04	2025-10-21	广东东阳光药业股份有限公司	一种酰胺化合物的共晶及其制备方法
US12161622B2 (en)	2021-05-04	2024-12-10	Janssen Pharmaceuticals, Inc.	Compositions and methods for the treatment of depression
BR112023023030A2 (pt)	2021-05-04	2024-02-15	Janssen Pharmaceuticals Inc	Composições e métodos para o tratamento de depressão
CA3247733A1 (en) *	2022-01-10	2023-07-13	Janssen Pharmaceuticals, Inc.	Compositions and methods of treating depression
MX2024008618A (es) *	2022-01-10	2024-09-25	Janssen Pharmaceuticals Inc	Composiciones y métodos para el tratamiento de la depresión.
IL315415A (en) *	2022-03-07	2024-11-01	Janssen Pharmaceuticals Inc	The compositions containing eticarpant
CA3254365A1 (en)	2022-03-07	2023-09-14	Janssen Pharmaceuticals, Inc.	POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION
CA3254503A1 (en) *	2022-03-07	2023-09-14	Janssen Pharmaceuticals, Inc.	PURE FORMS OF CRYSTALLINE ATICAPRANT
JP7176142B1 (ja)	2022-03-09	2022-11-21	直迪清瀬	各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457208A (en) *	1993-06-21	1995-10-10	Regents Of The University Of Minnesota	Kappa opioid receptor antagonists
CA2372040C (en) *	1999-05-12	2008-12-02	Francois Jenck	Imidazodiazepine derivative
CA2425124A1 (en) *	2000-10-05	2002-04-11	Hanns Mohler	Selective anxiolytic therapeutic agents
AU2002231206A1 (en) *	2000-12-21	2002-07-01	The Mclean Hospital Corporation	Treatment of depression
US6974824B2 (en)	2001-01-08	2005-12-13	Research Triangle Institute	Kappa opioid receptor ligands
US7119196B2 (en) *	2002-03-28	2006-10-10	Wisys Technology Foundation, Inc.	Anxiolytic agents with reduced sedative and ataxic effects
UA80437C2 (en) *	2002-09-19	2007-09-25	Lilly Co Eli	Diaryl ethers as opioid receptor antagonist
CA2518194A1 (en)	2003-03-07	2004-09-23	Eli Lilly And Company	6-substituted nicotinamide derivatives as opioid receptor antagonists
ATE406360T1 (de) *	2003-03-07	2008-09-15	Lilly Co Eli	Antagonisten der opioidrezeptoren
US7196100B2 (en) *	2003-12-12	2007-03-27	Eli Lilly And Company	Opioid receptor antagonists
EP1699783B1 (en) *	2003-12-22	2012-07-25	Eli Lilly And Company	Opioid receptor antagonists
CA2559207A1 (en) *	2004-03-12	2005-09-29	The Mclean Hospital Corporation	Salvinorin derivatives and uses thereof
ATE475640T1 (de) *	2004-03-12	2010-08-15	Lilly Co Eli	Antagonisten des opioidrezeptors
ATE399164T1 (de) *	2004-03-12	2008-07-15	Lilly Co Eli	Antagonisten des opioidrezeptors
EP1735268B1 (en) *	2004-03-15	2012-02-15	Eli Lilly And Company	Opioid receptor antagonists
ES2318472T3 (es) *	2004-03-15	2009-05-01	Eli Lilly And Company	Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad.
US8551986B2 (en) *	2005-12-08	2013-10-08	The Mclean Hospital Corporation	Treatment of sequelae of psychiatric disorders
RS51211B (sr)	2006-04-04	2010-12-31	Emodis Gmbh.	Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja
US8633175B2 (en)	2006-08-09	2014-01-21	Glaxosmithkline Llc	Compounds as antagonists or inverse agonists at opioid receptors
WO2008021851A2 (en)	2006-08-09	2008-02-21	Smithkline Beecham Corporation	Novel compounds as antagonists or inverse agonists for opioid receptors
KR20090051778A (ko)	2006-09-08	2009-05-22	화이자 프로덕츠 인코포레이티드	다이아릴 에터 유도체 및 이의 용도
NZ586225A (en) *	2008-01-22	2012-05-25	Lilly Co Eli	Kappa selective opioid receptor antagonist

2009
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown

Also Published As

Publication number	Publication date
KR20100095639A (ko)	2010-08-31
TWI422369B (zh)	2014-01-11
EA017484B1 (ru)	2012-12-28
MA32751B1 (fr)	2011-11-01
US20090186873A1 (en)	2009-07-23
SI2252581T1 (sl)	2012-09-28
DOP2010000222A (es)	2015-11-15
US8173695B2 (en)	2012-05-08
MX2010007849A (es)	2010-08-09
JP5345637B2 (ja)	2013-11-20
CN101925576A (zh)	2010-12-22
BRPI0907382B1 (pt)	2020-03-10
UA100715C2 (ru)	2013-01-25
ES2388708T3 (es)	2012-10-17
CA2713025A1 (en)	2009-07-30
KR101172170B1 (ko)	2012-08-07
HK1146822A1 (en)	2011-07-15
IL206038A (en)	2013-11-28
US20100197669A1 (en)	2010-08-05
WO2009094260A1 (en)	2009-07-30
AU2009206653A1 (en)	2009-07-30
PE20091317A1 (es)	2009-09-03
TN2010000306A1 (en)	2011-11-11
ZA201003908B (en)	2011-11-30
HRP20120558T1 (hr)	2012-10-31
EP2252581A1 (en)	2010-11-24
EP2252581B1 (en)	2012-06-20
JO2797B1 (en)	2014-03-15
CN101925576B (zh)	2013-02-06
ECSP10010365A (es)	2010-08-31
IL206038A0 (en)	2010-11-30
MY163014A (en)	2017-07-31
CO6290644A2 (es)	2011-06-20
US7709522B2 (en)	2010-05-04
JP2011524850A (ja)	2011-09-08
EA201070877A1 (ru)	2010-12-30
AR070158A1 (es)	2010-03-17
BRPI0907382A2 (pt)	2015-07-21
BRPI0907382B8 (pt)	2021-05-25
CY1113071T1 (el)	2016-04-13
TW200936129A (en)	2009-09-01
CA2713025C (en)	2012-12-04
NZ586225A (en)	2012-05-25
PT2252581E (pt)	2012-08-31
PL2252581T3 (pl)	2012-10-31
AU2009206653B2 (en)	2013-07-18

Publication	Publication Date	Title
DK2252581T3 (da)	2012-07-16	Kappa-selektiv opioidreceptorantagonist
HUS2200033I1 (hu)	2022-08-28	CGRP receptor antagonisták
HUS2200025I1 (hu)	2022-06-28	C5AR antagonisták
LTC2379069I2 (lt)	2022-05-25	S1p receptoriaus agonisto dozavimas
EP2350060A4 (en)	2012-07-25	Melanocortin receptor AGONISTS
BRPI0910118A2 (pt)	2015-12-29	antagonistas de receptores do glucagon
DK2821407T3 (da)	2017-01-02	Piperidinoncarboxamidazaindan-cgrp receptorantagonister
EP2150115A4 (en)	2011-08-03	CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
BRPI0923512A2 (pt)	2016-01-26	antagonistas de receptores de ácido lisofosfatídico
BRPI0913930A2 (pt)	2015-10-20	antagonistas de receptores de prostaglandinas d2
BRPI0919539A2 (pt)	2015-12-08	antagonistas de receptor de opioide periférico e empregos dos mesmos
BRPI0918760A2 (pt)	2015-12-29	compostos morfinanos
DK2501703T3 (da)	2013-10-14	Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI1016189A2 (pt)	2016-04-19	compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
HRP20170246T1 (hr)	2017-04-07	Režim doziranja za selektivni agonist s1p1-receptora
BRPI0810926A2 (pt)	2014-11-04	Antagonista de crig
ATE509022T1 (de)	2011-05-15	Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2081951T3 (da)	2010-08-09	Progesteron-receptorantagonister
SMT201400113B (it)	2014-11-10	Nalmefene cloridrato diidrato
DK2009992T3 (da)	2012-08-13	Il-8 receptor-antagonister
IL208355A0 (en)	2010-12-30	Heterocyclic copmpounds as adenosine receptor antagonist
DK2799428T3 (da)	2017-02-20	Glucagon-antagonister
HRP20160950T1 (hr)	2016-10-07	Polimorfi antagonista mglur5 receptora
BR112012003976A2 (pt)	2016-03-29	antagonistas de receptor glyt1 carbocíclico
BRPI0821611A2 (pt)	2015-08-25	Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas de receptor opióide mu